GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (FRA:1GDA) » Definitions » Shiller PE Ratio

Zevra Therapeutics (FRA:1GDA) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zevra Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Zevra Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics Shiller PE Ratio Chart

Zevra Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zevra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zevra Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Zevra Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Shiller PE Ratio falls into.



Zevra Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zevra Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Zevra Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.368/131.7762*131.7762
=-0.368

Current CPI (Mar. 2024) = 131.7762.

Zevra Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -5.377 100.560 -7.046
201409 -11.327 100.428 -14.863
201412 -12.483 99.070 -16.604
201503 -7.176 99.621 -9.492
201506 -34.927 100.684 -45.713
201509 -9.694 100.392 -12.725
201512 -9.400 99.792 -12.413
201603 -2.874 100.470 -3.770
201606 8.259 101.688 10.703
201609 -13.116 101.861 -16.968
201612 -10.314 101.863 -13.343
201703 -16.606 102.862 -21.274
201706 -6.266 103.349 -7.990
201709 -9.128 104.136 -11.551
201712 -9.734 104.011 -12.332
201803 -22.968 105.290 -28.746
201806 -12.463 106.317 -15.447
201809 -12.889 106.507 -15.947
201812 2.532 105.998 3.148
201903 -6.514 107.251 -8.004
201906 -4.673 108.070 -5.698
201909 0.872 108.329 1.061
201912 -2.547 108.420 -3.096
202003 -1.738 108.902 -2.103
202006 0.186 108.767 0.225
202009 -0.577 109.815 -0.692
202012 -0.929 109.897 -1.114
202103 -2.092 111.754 -2.467
202106 -0.332 114.631 -0.382
202109 -0.043 115.734 -0.049
202112 0.044 117.630 0.049
202203 -0.045 121.301 -0.049
202206 -0.662 125.017 -0.698
202209 -0.192 125.227 -0.202
202212 0.151 125.222 0.159
202303 -0.355 127.348 -0.367
202306 -0.138 128.729 -0.141
202309 -0.375 129.860 -0.381
202312 -0.367 129.419 -0.374
202403 -0.368 131.776 -0.368

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zevra Therapeutics  (FRA:1GDA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Zevra Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zevra Therapeutics (FRA:1GDA) Business Description

Traded in Other Exchanges
Address
1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747
Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Zevra Therapeutics (FRA:1GDA) Headlines

No Headlines